Your browser is no longer supported. Please, upgrade your browser.
PDSB PDS Biotechnology Corporation daily Stock Chart
PDS Biotechnology Corporation
Index- P/E- EPS (ttm)-26.25 Insider Own6.50% Shs Outstand5.56M Perf Week9.56%
Market Cap36.97M Forward P/E- EPS next Y- Insider Trans- Shs Float1.42M Perf Month17.49%
Income-40.90M PEG- EPS next Q- Inst Own26.90% Short Float3.85% Perf Quarter-16.25%
Sales- P/S- EPS this Y38.30% Inst Trans-1.38% Short Ratio0.37 Perf Half Y-50.75%
Book/sh-6.52 P/B- EPS next Y- ROA- Target Price1.00 Perf Year-67.08%
Cash/sh4.78 P/C1.39 EPS next 5Y- ROE- 52W Range5.03 - 25.40 Perf YTD3.58%
Dividend- P/FCF- EPS past 5Y-34.70% ROI- 52W High-73.82% Beta3.19
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low32.21% ATR0.86
Employees10 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)49.43 Volatility16.39% 12.44%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.63 Prev Close7.20
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume147.47K Price6.65
Recom- SMA204.01% SMA50-8.12% SMA200-41.62% Volume93,502 Change-7.64%
May-17-19 12:07PM  Learning When To Pick Your Battles Starts With Winning Setups Benzinga -6.74%
May-15-19 08:30AM  PDS Biotechnology Announces Publication Supporting Novel Mechanisms of Action of its Proprietary Versamune® Platform in Cancer Immunotherapy GlobeNewswire +41.37%
May-14-19 05:22PM  PDS Biotechnology: 1Q Earnings Snapshot Associated Press
04:10PM  PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Apr-08-19 08:00AM  PDS Biotechnology Appoints Stephen Glover to its Board of Directors GlobeNewswire -8.86%
PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. It develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company lead product candidate is PDS0101, an immunotherapeutic for the treatment of cancer. Its synthetic lipid-based immunotherapy platform is Versamune. The company develops Versamune based products for the treatment of cancer. PDS Biotechnology Corporation is based in Berkeley Heights, New Jersey.